Vladimir Serebryany

Vladimir Serebryany has extensive work experience in the field of process chemistry and pharmaceutical research. Vladimir is currently the Director of Process Chemistry at Aligos Therapeutics, a position they have held since March 2022. Prior to this role, they worked as a Research Fellow and Principal Scientist in Process Chemistry at the same company, from 2020 to 2022 and 2018 to 2020, respectively.

Before joining Aligos Therapeutics, Vladimir worked at Alios BioPharma from 2011 to 2018. During their time there, they held the positions of Principal Scientist and Senior Scientist. Vladimir'sresponsibilities included synthetic development for lead molecules and the synthesis of RSV inhibitor Lumicitabine, which was used in clinical trials.

From 2005 to 2011, they worked at InterMune as a Principal Scientist, contributing to various drug discovery and development projects in areas of pulmonology and hepatology. Vladimir played a key role in the design and synthesis of antifibrotic compounds and the optimization of HCV helicase inhibitors.

Earlier in their career, Vladimir held positions as a Senior Scientist at Transgenomic Inc. and a Scientist at Ribozyme Pharmaceuticals. Vladimir also worked as a Research Fellow at the American Health Foundation. Vladimir'sscientific career began at the Vitamin Research Institute in Moscow, Russia, where they worked as a Scientist for almost two decades, from 1981 to 1999.

Vladimir Serebryany obtained their Bs/Ms degree in Organic Chemistry from the Lomonosov Moscow State Academy of Fine Chemical Technology (MITHT) in 1981. During this time, they focused on the fields of Vitamin A chemistry and Bacteriorhodopsin analogs. Following this, from 1989 to 1992, they pursued a PhD in Organic Chemistry at the Chemical Pharmaceutical Research Institute (NIHFI) in Moscow, Russia (ВНИХФИ).